Laurie Withington
Principal Analyst
USA
+13 year(s) experience
Laurie maintains and updates the products she works on, mainly Trialtrove and Analytics, and provides insight
and analysis in blogs and whitepapers on various diseases.
She initially worked in the Trialscape group when she joined Informa in 2008, providing custom analytics
projects to clients. Following this, she worked in the Trialtrove group in oncology, as well as in CNS,
autoimmune, and ophthalmology.
Before joining Informa, Laurie was a Cardiovascular/Metabolic Disease Portfolio Manager at Wyeth Pharma,
where she managed the risk, potential success, and logistics of the drugs in pipeline leading up to Phase I.
Trialtrove
The wearable technology market is rapidly growing, and impacting many different areas of our culture such as social interaction, entertainment, environment, self-awareness, and healthcare. Techcrunch has forecasted sales of wearable devices worldwide this year at $30.5BN in total revenue . As more money is spent on wearable devices, innovation expands, which in turn increases the many facets of our lives that these devices can be incorporated into.
Topic Clinical trials
Trialtrove
There have been numerous failures of Alzheimer’s dementia drugs in the past five years.
Topic Alzheimers
Citeline
Two new diseases were recently added to Trialtrove, retinitis pigmentosa and spinal muscular atrophy.
Topic Rare Disease
Pharmaprojects
A report that analyses the current clinical development landscape for Parkinson's Disease
Topic Parkinsons disease